tbuckley/cabot-search huggingface dataset:
Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies
Authors: Angela Spelsberg, Christof Prugger, Peter Doshi, Kerstin Ostrowski, Thomas Witte, Dieter Hüsgen, Ulrich Keil
Journal: BMJ (2017)

To investigate the practice of post-marketing studies in Germany during a three year period and to evaluate whether these trials meet the aims specified in the German Medicinal Products Act. Survey of notifications submitted to German regulatory agencies before post-marketing studies were carried out, 2008-10. Notifications obtained through freedom of information requests to the three authorities responsible for registering post-marketing studies in Germany. Descriptive statistics of post-marketing studies, including the products under study, intended number of patients, intended number of participating physicians, proposed remunerations, study plan and protocol, and availability of associated scientific publications and reports on adverse drug reactions. Information was obtained from 558 studies, with a median of 600 (mean 2331, range 2-75 000) patients and 63 (270, 0-7000) participating physicians per study. The median remuneration to physicians per patient was €200 (€441, €0-€7280) (£170, £0-£6200; $215, $0-$7820), with a total remuneration cost of more than €217m for 558 studies registered over the three year period. The median remuneration per participating physician per study was €2000 (mean €19 424), ranging from €0 to €2 080 000. There was a broad range of drugs and non-drug products, of which only a third represented recently approved drugs. In many notifications, data, information, and results were, by contract, strictly confidential and the sole property of the respective sponsor. No single adverse drug reaction report could be identified from any of the 558 post-marketing studies. Less than 1% of studies could be verified as published in scientific journals. Post-marketing studies are not improving drug safety surveillance. Sample sizes are generally too small to allow the detection of rare adverse drug reactions, and many participating physicians are strictly obliged to maintain confidentiality towards the sponsor. High remuneration and strict confidentiality clauses in these studies could influence the physicians' reporting behaviours of adverse drug reactions.
Genetic Sequencing of Adult T-Cell Leukemia/Lymphoma in the Caribbean Population Shows a Distinct Mutational Profile When Compared to the Japanese Cohort
Authors: Urvi A Shah, B. Hilda Ye, Jeff Hall, Yanhua Wang, Ronald Rice, Rizwan Naeem, Amara Gayathri Nandikolla, Swati Goel, Ioannis Mantzaris, Aditi Shastri, Olga Derman, Noah Kornblum, Ira Braunschweig, Amit Verma, Murali Janakiram
Journal: Blood (2016)
444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ)
Authors: T.S.K. Mok, G. Scagliotti, T.M. Kim, L. Crino, G. Liu, C. Gridelli, S. Novello, K. Kiura, A. Bearz, O. Gautschi, E. Felip, M. Nishio, D.R. Spigel, P. Urban, S. Deudon, C. Zheng, A.T. Shaw
Journal: Annals of Oncology (2016)
445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK- rearranged (ALK +) non-small cell lung cancer (NSCLC) previously treated with crizotinib
Authors: L. Zhang, Y. Shi, D.S.W. Tan, B. Hu, L. Xiaoqing, Y. Cheng, J. Zhou, T. An, Y. Lu, B. Zhu, C. Bai, A. Jappe, V.Q. Passos, Y.Y. Lau, Q. Wang, Y.-L. Wu
Journal: Annals of Oncology (2016)
Tcf3/Pbx1 Fusion Molecule Induces the Transcription of Prox-1 and Vascular Endothelial Growth Factor Receptor Type-3
Authors: Yoko Oka, Ryosuke Shirasaki, Haruko Tashiro, Tadashi Yamamoto, Nobu Akiyama, Kazuo Kawasugi, Naoki Shirafuji
Journal: Blood (2011)
Pegfilgrastim and Daily Granulocyte Colony-Stimulating Factor (G-CSF) Patterns of Use and Neutropenia-Related Outcomes in Cancer Patients in Spain: Results of the Learn Study.
Authors: D. Almenar, J. Mayans, O. Juan, J.M. García Bueno, Ji Jalón, A. Frau, M. Guinot, P. Cerezuela, E. García Buscallà, J. Sánchez
Journal: Blood (2005)
Comparison of Hispanic and non-Hispanic patients with HCC.
Authors: Atinuke Babalola, Rebecca A. Miksad, Olubunmi Oladunjoye, Ugonna Nwosu, Nelsy Castro-Webb, Neeharika Srivastava, Bethany Burns
Journal: Journal of Clinical Oncology (2014)

294 Background: In the U.S., Hispanics have a higher incidence of hepatocellular cancer (HCC) and higher disease-specific mortality. The country of origin for Hispanics varies throughout the U.S. However, little is known about Hispanics with HCC in the Northeast. We compared Hispanic and non-Hispanic patients with HCC at a Boston teaching hospital. Methods: Hispanic patients with HCC seen at Beth Israel Deaconess Medical Center (BIDMC) from 1998-2012 were identified in our database. Ethnicity was determined from demographic and language preference information in electronic medical records and supplemented by comparing surnames with the 1990 Census Spanish Surname List. The comparison group was identified by randomly choosing non-Hispanic patients diagnosed the same years as Hispanic patients. We compared both groups using Chi Squared test. Results: 59 Hispanic and 89 non-Hispanic patients with HCC were included in the analysis. The majority (48%) of Hispanic HCC patients were Puerto Rican. Although the median age at diagnosis was similar (59.1 vs 60.3 years for Hispanics and non-Hispanics), there were more women in the Hispanic cohort (28.8% vs 12.4% p0.012). Hispanics had greater odds of not having private insurance (OR 4.24, 95%CI: 2.101, 8.554). Evaluation of HCC risk factors revealed Hispanics were significantly more likely to have hepatitis C (OR 3.68, 95% CI: 1.830, 7.420). In addition, the incidence of Metabolic Syndrome was significantly higher for Hispanics (44.7% vs. 21.7% p0.025). Although individual components of metabolic syndrome were higher in Hispanics, they were not statistically significant: hypertension (52.5% vs 40.4%), Diabetes Mellitus (39% vs 25%), BMI ≥ 30 (39% vs 27%), hypertrigylceridemia (57% vs 52%) and low HDL levels (50% vs 41%). Hispanics were more likely to have received Transarterial Chemoembolization (TACE) and Radiofrequency ablation (RFA) treatments (OR 2.48, 95% CI: 1.261, 4.858). Conclusions: Hispanic HCC patients at BIDMC were more likely to have hepatitis C, metabolic syndrome and to be female than their non-Hispanic counterparts. Outreach to Hispanic communities to identify patients with hepatitis C and metabolic syndrome, particularly in women, may improve HCC prevention, screening and treatment outcomes.
Metabolic and Deep Immune Profiling Reveal Coordinate Effects on Immune Function in Asthma and Obesity
Authors: Sarah E. Henrickson, Sasikanth Manne, Ramin S. Herati, Laura A. Vella, Bertram Bengsch, Scott E. Hensley, Joshua D. Rabinowitz, Susan Coffin, E. John Wherry
Journal: Journal of Allergy and Clinical Immunology (2017)
Patient-reported outcomes following choice for contralateral prophylactic mastectomy.
Authors: Eun-Sil Shelley Hwang, Christel Rushing, Tracie D. Locklear, Greg Samsa, Amy Pickar Abernethy, Dunya M Atisha
Journal: Journal of Clinical Oncology (2015)

9554 Background: Retrospective data show that the rate of contralateral prophylactic mastectomies (CPMs) is increasing; meanwhile, parallel information informing impact of CPM on quality of life (QOL) is lacking. We undertook this study to ascertain whether patient-reported outcomes (PRO), and more specifically QOL, differed between women who did or did not elect CPM. Methods: Women recruited from the Army of Women (AOW) with a history of breast cancer surgery took electronically-administered surveys including a background survey to collect patient, disease, and procedure specific factors, as well as the BREAST-Q, a well-validated breast surgery outcomes patient reporting tool. Descriptive statistics, univariate hypothesis testing, and regression analysis were used to evaluate the association of CPM with PRO scores in 4 QOL domains incorporated in the BREAST-Q (satisfaction with breasts, and psychosocial, physical and sexual well-being). Results: 7628 women completed questionnaires; of these, 4152 had mastectomy and 1519 (37%) reported receipt of CPM. Women undergoing CPM were younger (median age 53.7 y vs. 59.3 y, p < 0.0001) and reported earlier breast cancer stage at presentation than those who did not choose CPM. In univariate analysis, mean breast satisfaction was significantly higher among the CPM group (60.4 vs. 58.1, p = 0.0005) and mean physical well-being was significantly higher among those who did not have a CPM (76.6.vs. 74.6, p = 0.0002). The groups did not differ with respect to psychosocial or sexual well-being. On multivariable linear regression the CPM group continued to report higher breast satisfaction (p = 0.0019) but reported no difference from the non-CPM group in the other QOL domains. Psychosocial well-being improved over time for both CPM and non-CPM groups (p < 0.0001), but did not differ significantly within time interval since surgery. Conclusions: Choice for CPM was only associated with improved QOL in the breast satisfaction domain and did not impact psychosocial, physical and sexual well-being after adjustment for other factors known to influence QOL. Such PRO data are important to consider when counseling women contemplating CPM as part of their breast cancer treatment.
Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling
Authors: Sanne Lugthart, Maria E Figueroa, Peter JM Valk, Yushan Li, Claudia Erpelinck-Verschueren, John Greally, Bob Löwenberg, Ari Melnick, Ruud Delwel
Journal: Blood (2008)
P08.70 Prognostic and predictive factors in primary Glioblastoma Multiforme WHO grade IV patients with resection: A single-institution study
Authors: O. Kalita, M. Hajduch, R. Trojanec, M. Megova, M. Vaverka, L. Hrabalek, M. Zlevorova, J. Drabek, L. Tuckova, J. Vrbková
Journal: Neuro-Oncology (2016)

BACKGROUND: Several studies observed that age is the most significant factor associated with poor prognosis in patients with glioblastoma (GBM).Age is not the only factor in the choice of treatment in elderly patients.Recent studies in cancer patients have shown that comorbidities should be considered a contraindication to aggressive approach, as they can influence the treatment compliance and/or patients' survival.Co-morbidities are often underestimated in patients affected by GBM, and their role on the outcome of elderly GBM patients has been poorly explored.This study evaluated the impact of comorbidities on outcomes in elderly GBM patients.METHODS: Patients over 65 years affected by GBM were consecutively enrolled in a prospective observational study.Demographic and clinical characteristics were recorded.For each patient, comorbid conditions were indentified with the modified version of the Cumulative Illness Rating Scale (CIRS) [21].Results Sixty-six elderly patients [36 males and 30 females] with GBM were enrolled in the study.The median age at diagnosis was 73 years.The median PFS was 8 months with a median of OS of 18 months.The univariate analysis demonstrates that the variables useful in predicting disease progression were: a severity of CIRS-CI compared with a slight CIRS-CI (HR=3.78,95% CIs from 1.32 to 10.88 p=0.013) and the CM greater than 2 compared with the CM less or equal to 2 (HR=2.01,95% CIs from 1.03 to 3.93 p=0.040).At the multivariate analysis the severity of CIRS-CI showed a statistical trend (serious vs slight HR=3.01,95% CIs from 0.93 to 9.72 p=0.065) (table 2).Univariate analysis of the whole cohort found that having an age ≥75 years (>75 vs ≤75; HR=3.19, 95% CIs from 1.68 to 6.07 p<0.001), intermediate or high CIRS-CI (intermediate vs slight; HR=2.21, 95% CIs from 1.04 to 4.67 p=0.038 and high vs slight; HR=8.42, 95% CIs from 3.44 to 20.58 p2 vs≤2; HR=2.24, 95% CIs from 1.16 to 4.32 p=0.016) were associated with shorter survival (table 3).The multivariate analysis confirmed the predictive role on survival for age ≥ 75 years (HR=4.20,95% CIs from 1.99 to 8.85 p>0.001), intermediate CIRS-CI (HR=2.26,95% CIs from 1.06 to 4.81 p=0.034) and high CIRS-CI (HR=8.63,95% CIs from 2.98 to 24.94 p<0.001) (table 3).The CM was not confirmed in the multivariate analysis.Discussion: Lastly, our findings need to be replicated in larger samples.If the prognostic role of comorbidity measured by CIRS on the outcome is confirmed, it would be important to add it in the algorithm for treatment choice in elderly GBM patients.Overall survival
Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting
Authors: Catherine M Claussen, Tammy Chuang, Jatin Shah, Hans Lee, Nina Shah, Krina K Patel, Qaiser Bashir, Simrit Parmar, Sheeba Thomas, Muzaffar Qazilbash, Richard Eric Davis, Sattva S. Neelapu, Donna Weber, Robert Z. Orlowski, Lei Feng, Elisabet E. Manasanch
Journal: Blood (2015)
Inhibition of DLEU1 Following siRNA Transfection in Burkett’s Lymphoma (BL): Implication for Tumor Repressor Role of DLEU1 in C-Myc-Activated BL Lymphomagenesis
Authors: Nancy Day, Janet Ayello, Ian Waxman, Evan Shereck, Catherine McGuinn, Carmella van de Ven, Megan S Lim, Sherrie L. Perkins, Mitchell S. Cairo
Journal: Blood (2008)
Annals Story Slam - The Valve and the Nap
Authors: Steven Breecker
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - The Valve and the NapFREESteven Breecker, MDSteven Breecker, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0013 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The Valve and the Nap "The Valve and the Nap," by Steven Breecker, MD (Duration 6:43)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Steven Breecker, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Basophil Microparticles in Blood and Nasal Lavage of Chronic Rhinosinusitis and Aspirin Exacerbated Respiratory Disease; New Biomarkers for Basophil Activation
Authors: Toru Takahashi, Atsushi Kato, Whitney W. Stevens, Lydia A. Suh, James Norton, Roderick G. Carter, Kathleen E. Harris, Anju T. Peters, Kathryn E. Hulse, Leslie C. Grammer, Kevin C. Welch, Stephanie Shintani Smith, Bruce K. Tan, David B. Conley, Robert C. Kern, Bruce S. Bochner, Robert P. Schleimer
Journal: Journal of Allergy and Clinical Immunology (2017)
Scientists Discover Off Switch for Genome Editing Technique
Authors: Tracy Hampton
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study
Authors: Lakshmi N Yatham, Sylvia Mackala, Jayasree Basivireddy, Sharon Ahn, Nazlin Walji, Chen Hu, Raymond W Lam, Ivan J Torres
Journal: The Lancet Psychiatry (2017)
Novel insight in diarrhoea-predominant IBS: miRNAs modulate barrier function
Authors: Mira M Wouters
Journal: Gut (2017)

IBS is a functional GI disorder characterised by abdominal bloating, increased visceral pain perception and an altered defaecation pattern in the absence of an organic cause. The underlying pathophysiological mechanisms that lead to abdominal pain and chronic symptoms in IBS are not fully understood. A common finding is the presence of increased mucosal intestinal permeability and an altered distribution of cell-to-cell adhesion proteins in the intestinal epithelium.1 In particular, patients with diarrhoea-predominant IBS (IBS-D)2 suffer from increased permeability, and this increase correlates with aberrant visceral sensitivity.3 Based on these observations, it is currently hypothesised that impairment of the intestinal barrier integrity facilitates the entrance of food or microbial antigens into the intestinal mucosa, thereby stimulating the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Bioactive mediators released by these cells, including proteases, histamine and prostanoids, participate in the perpetuation of the permeability dysfunction4 and contribute to the activation and sensitisation of (sensory) neurons5 leading to aberrant abdominal pain perception and changes in bowel habits.

Both endogenous (genetic) and environmental factors can lead to intestinal barrier impairment, but psychological stress and infectious gastroenteritis are probably the best known and strongest triggers. Increased colonic paracellular permeability has indeed been extensively observed in both chronic and acute stress murine models,6 and the connection between stress and permeability is slowly evolving in humans.7 On the other hand, infectious gastroenteritis is a common trigger for IBS, as the risk of developing IBS after acute gastroenteritis is sixfold greater than that …
Molecular imaging of PgP/BCRP inhibition at the blood brain barrier using elacridar and [11C]erlotinib PET
Authors: R.B. Verheijen, M. Yaqub, E. Sawicki, O. van Tellingen, A.A. Lammertsma, B. Nuijen, J.H.M. Schellens, J.H. Beijnen, A.D.R. Huitema, N.H. Hendrikse, N. Steeghs
Journal: Annals of Oncology (2016)
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Authors: Jose Luis Calleja, Javier Crespo, Diego Rincón, Belén Ruiz-Antorán, Inmaculada Fernandez, Christie Perelló, Francisco Gea, Sabela Lens, Javier García-Samaniego, Begoña Sacristán, María García-Eliz, Susana Llerena, Juan Manuel Pascasio, Juan Turnes, Xavier Torras, Rosa Maria Morillas, Jordi Llaneras, Miguel A. Serra, Moises Diago, Conrado Fernández Rodriguez, Javier Ampuero, Francisco Jorquera, Miguel A. Simon, Juan Arenas, Carmen Alvarez Navascues, Rafael Bañares, Raquel Muñoz, Agustin Albillos, Zoe Mariño
Journal: Journal of Hepatology (2017)
505PD Elevated blood neutrophil-to-lymphocyte ratio is associated with poor clinical outcome in patients with synovial sarcoma
Authors: L. Zhou, J.Y. Chan, G.F.M. Tan, C.L.W. Lim, W.L. Goh, S. Sathiyamoorthy, K. Sittampalam, J. Teh, F. Chin, M.H. Tan, K.C. Soo, M. Teo, M. Farid, R. Quek
Journal: Annals of Oncology (2016)
Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
Authors: G. Procopio, G. Paganelli, M. Cabria, E. Cortesi, M. Tucci, A. Farnesi, L. Mango, S. Baldari, A. Hamzaj, O. Caffo, P. Marchetti, F. Dalla Pozza, P. Zucali, R. Barsanti, D. Heinrich
Journal: Annals of Oncology (2017)
Human Herpesvirus 8 Protein K1 Interferes with Fas-Mediated Apoptosis Induces Clonal Growth and Lymphoid Hyperplasia
Authors: Ronghua Tao, Zuzana Berkova, Shu Wang, Suizhao Wang, Jillian Wise, Hoyoung Maeng, Felipe Samaniego
Journal: Blood (2008)
Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Authors: Ahmed Atef Ibrahim, Christian Schmithals, Erik Kowarz, Verena Köberle, Bianca Kakoschky, Thomas Pleli, Otto Kollmar, Scarlett Nitsch, Oliver Waidmann, Fabian Finkelmeier, Stefan Zeuzem, Horst-Werner Korf, Tobias Schmid, Andreas Weigert, Bernd Kronenberger, Rolf Marschalek, Albrecht Piiper
Journal: Clinical Cancer Research (2017)

Purpose: A role of Dicer, which converts precursor miRNAs to mature miRNAs, in the tumor-promoting effect of hypoxia is currently emerging in some tumor entities. Its role in hepatocellular carcinoma (HCC) is unknown.Experimental Design: HepG2 and Huh-7 cells were stably transfected with an inducible Dicer expression vector and were exposed to hypoxia/normoxia. HepG2-Dicer xenografts were established in nude mice; hypoxic areas and Dicer were detected in HCC xenografts and HCCs from mice with endogenous hepatocarcinogenesis; and epithelial-mesenchymal transition (EMT) markers were analyzed by immunohistochemistry or by immunoblotting. The correlation between Dicer and carbonic anhydrase 9 (CA9), a marker of hypoxia, was investigated in resected human HCCs.Results: Hypoxia increased EMT markers in vitro and in vivo and led to a downregulation of Dicer in HCC cells. The levels of Dicer were downregulated in hypoxic tumor regions in mice with endogenous hepatocarcinogenesis and in HepG2 xenografts. In human HCCs, the levels of Dicer correlated inversely with those of CA9, indicating that the negative regulation of Dicer by hypoxia also applies to HCC patients. Forced expression of Dicer prevented the hypoxia-induced increase in hypoxia-inducible factor 1α (HIF1α), HIF2α, hypoxia-inducible genes (CA9, glucose transporter 1), EMT markers, and cell migration.Conclusions: We here identify downmodulation of Dicer as novel essential process in hypoxia-induced EMT in HCC and demonstrate that induced expression of Dicer counteracted hypoxia-induced EMT. Thus, targeting hypoxia-induced downmodulation of Dicer is a promising novel strategy to reduce HCC progression. Clin Cancer Res; 23(14); 3896-905. ©2017 AACR.
Monocyte Subset Analysis Accurately Distinguishes Chronic Myelomonocytic Leukemia (CMML) from Myelodysplastic Syndromes (MDS) and Is Associated with a Favorable MDS Prognosis
Authors: Chetasi Talati, Ling Zhang, Ghada Shaheen, Andrew Kuykendall, Markus Ball, Qing Zhang, Jeffrey E. Lancet, Kenneth S. Zuckerman, Alan F. List, Rami S. Komrokji, Lynn C. Moscinski, Eric Padron
Journal: Blood (2016)